Barclays PLC Satsuma Pharmaceuticals, Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 04, 2023
SELL
$0.7 - $1.07 $36 - $55
-52 Reduced 0.33%
15,841 $11,000
Q4 2022

Feb 13, 2023
SELL
$0.61 - $5.06 $123,835 - $1.03 Million
-203,009 Reduced 92.74%
15,893 $14,000
Q3 2022

Nov 03, 2022
BUY
$4.19 - $7.95 $68,816 - $130,570
16,424 Added 8.11%
218,902 $1.31 Million
Q1 2022

May 16, 2022
BUY
$3.78 - $5.32 $765,366 - $1.08 Million
202,478 New
202,478 $769,000

About Satsuma Pharmaceuticals, Inc.

STSA Quotes by TradingView
  • Ticker STSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,587,500
  • Description
  • Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...
More about STSA
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email